ARS Pharmaceuticals director granted 30,000 stock options
ARS Pharmaceuticals director Saqib Islam received a stock option grant covering 30,000 shares of Common Stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
ARS Pharmaceuticals director Saqib Islam received a stock option grant covering 30,000 shares of Common Stock. The option has an exercise price of $10.54 per share and expires on June 23, 2036. These options vest in full on the earlier of June 24, 2027 or the company’s 2027 annual meeting of stockholders. Following this grant, Islam holds 30,000 stock options directly.
Insider Trade Summary
Grant/Award: 30,000 shares
Grant/Award
1 txn
Insider
Islam Saqib
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 30,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 30,000 contracts (Direct)
Footnotes (1)
- F1. The shares subject to the option will vest in full on the earlier of June 24, 2027 or the date of the Issuer's 2027 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.
Key Figures
Option grant size: 30,000 options
Exercise price: $10.54 per share
Expiration date: June 23, 2036
+2 more
5 metrics
Option grant size
30,000 options
Stock Option (right to buy) covering Common Stock
Exercise price
$10.54 per share
Conversion or exercise price of stock option
Expiration date
June 23, 2036
Option expiration date
Vesting trigger date
June 24, 2027
Vests on earlier of this date or 2027 annual meeting
Post-grant option holdings
30,000 options
Total derivative shares following transaction
Key Terms
Stock Option (right to buy), exercise price, vest in full, annual meeting of stockholders
4 terms
Stock Option (right to buy) financial
"security_title: "Stock Option (right to buy)""
exercise price financial
"conversion_or_exercise_price: "10.5400""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vest in full financial
"The shares subject to the option will vest in full on the earlier of June 24, 2027"
annual meeting of stockholders financial
"or the date of the Issuer's 2027 annual meeting of stockholders"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did ARS Pharmaceuticals (SPRY) director Saqib Islam report in this Form 4?
Saqib Islam reported receiving a stock option grant for 30,000 shares of ARS Pharmaceuticals Common Stock. The options are a compensation-related award, not an open-market purchase or sale, and give him the right to buy shares at a fixed price in the future.
How many ARS Pharmaceuticals (SPRY) options did Saqib Islam receive and at what price?
He received 30,000 stock options, each with an exercise price of $10.54 per share. This means he can purchase up to 30,000 ARS Pharmaceuticals shares at $10.54, regardless of the market price, once the options are vested and exercisable.
When do Saqib Islam’s ARS Pharmaceuticals (SPRY) stock options vest?
The 30,000 stock options will vest in full on the earlier of June 24, 2027 or the date of ARS Pharmaceuticals’ 2027 annual meeting of stockholders. Vesting must occur before the options can be exercised to purchase Common Stock.
When do Saqib Islam’s ARS Pharmaceuticals (SPRY) stock options expire?
These stock options expire on June 23, 2036. After that expiration date, any unexercised options become worthless. Islam must both wait for vesting and exercise before expiration to acquire ARS Pharmaceuticals Common Stock under this grant.
Is this ARS Pharmaceuticals (SPRY) Form 4 a market trade or a compensation grant?
This Form 4 reports a grant or award acquisition of stock options, not a market trade. The company awarded 30,000 options as compensation, giving Saqib Islam a potential future right to buy shares at $10.54 instead of reporting an open-market buy or sell.
How many ARS Pharmaceuticals (SPRY) options does Saqib Islam hold after this transaction?
After this grant, Saqib Islam holds 30,000 stock options directly, as indicated by the total shares following the transaction. The filing does not list additional derivative positions in the derivative summary beyond this new award.
AI-generated analysis. How Rhea-AI works. Not financial advice.
